Diuretic Selection in Chronic Kidney Disease

Introduction to Diuretic Therapy

The American College of Cardiology recommends thiazide diuretics as first-line agents for hypertension treatment across all CKD stages, alongside ACE inhibitors, ARBs, and calcium channel blockers 2
The National Kidney Foundation's KDOQI work group specifically disagreed with older statements suggesting thiazides should not be used in advanced CKD due to lack of efficacy 2
Thiazide treatment should not be automatically discontinued when eGFR decreases to <30 mL/min/1.73 m², as supported by the American Journal of Kidney Diseases 1

Chlorthalidone 25 mg reduced 24-hour ambulatory blood pressure by 10.5 ± 3.1 mm Hg in patients with mean eGFR of 26.8 mL/min/1.73 m², according to the American Heart Association 1, 2
Thiazides have been shown effective in reducing blood pressure even in advanced CKD (eGFR <30 mL/min/1.73 m²), as stated by the National Kidney Foundation 1

Loop diuretics (furosemide, bumetanide, torsemide) have emerged as the preferred agents for managing fluid retention in heart failure, not primarily for blood pressure control, as recommended by the American College of Cardiology 3
Loop diuretics are indicated when thiazides alone cannot adequately control volume status, according to the European Society of Cardiology 3

Use chlorthalidone 12.5-25 mg daily as first-line therapy for patients with stage 1-3 CKD (eGFR ≥30 mL/min/1.73 m²), as suggested by the American Journal of Kidney Diseases 2
Consider chlorthalidone 25 mg daily for resistant hypertension in patients with stage 4-5 CKD (eGFR <30 mL/min/1.73 m²), according to the National Kidney Foundation 2
Reserve furosemide for patients with evidence of fluid retention (edema, pulmonary congestion, volume overload), as recommended by the American College of Cardiology 3

Check electrolytes (sodium, potassium) and renal function within 2-4 weeks after initiating thiazide therapy, as suggested by the American Journal of Kidney Diseases 1, 2
Follow up every 6-8 weeks until blood pressure goal is safely achieved, according to the National Kidney Foundation 1
Monitor closely for hypokalemia, hyponatremia, hyperuricemia, and volume depletion, as recommended by the European Society of Cardiology 1

Do not automatically discontinue thiazides when eGFR falls below 30 mL/min/1.73 m² - this outdated practice contradicts current evidence, as stated by the American Journal of Kidney Diseases 1, 2
Avoid potassium-sparing diuretics when GFR <45 mL/min due to hyperkalemia risk, as recommended by the National Kidney Foundation 1, 2
Never combine ACE inhibitors with ARBs, regardless of diuretic use, as suggested by the American College of Cardiology 2
Do not use furosemide as first-line therapy for blood pressure control - it is less effective than thiazides for this indication and should be reserved for volume management, according to the American Heart Association 3